002422 科伦药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入4,259,245-2.98%18,512,91921,812,41421,453,92919,038,216
减:营业总成本3,990,1267.03%16,435,76517,850,87418,277,36317,223,484
    其中:营业成本2,329,2233.37%9,655,23710,536,82110,205,5359,040,158
               财务费用11,708183.70%71,49966,179233,761479,834
               资产减值损失0--(116,225)(130,590)(130,551)(44,113)
公允价值变动收益7,195-5.70%27,61219,89814,6669,861
投资收益62,9302.64%210,413345,018358,882234,580
    其中:对联营企业和合营企业的投资收益59,1651.00%182,889320,466352,105228,194
营业利润356,491-55.09%2,521,0504,426,3213,654,1432,195,142
利润总额441,048-42.96%2,403,8364,285,3593,580,4262,067,919
减:所得税费用(31,652)-127.86%526,624923,404933,787363,697
净利润472,700-28.33%1,877,2113,361,9542,646,6391,704,221
减:非控股权益19,000-74.78%175,276426,062190,527(1,103)
股东净利润453,701-22.34%1,701,9352,935,8922,456,1121,705,324

市场价值指针
每股收益 (元) *0.290-21.62%1.0701.8601.6901.220
每股派息 (元) *----0.5940.7630.8000.616
每股净资产 (元) *15.4186.68%15.15914.03713.00910.864
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容